Carregando...
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...
Na minha lista:
| Publicado no: | Clin Exp Immunol |
|---|---|
| Principais autores: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7405500/ https://ncbi.nlm.nih.gov/pubmed/32671831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13495 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|